Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Painless glucose check? new device could end finger pricks

NCT ID NCT07088497

Diagnosis Sponsor: Revlis Biotech Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new device called the Cmate blood glucose analyzer, which measures blood sugar without needing a finger prick. Researchers compared its readings to standard blood tests in 40 healthy, pre-diabetic, and diabetic adults. The goal is to see if this non-invasive method is accurate enough for home use, potentially making blood sugar monitoring less painful and more convenient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
non-invasive blood glucose measurement system
What this could lead to
If successful, this could lead to a painless, needle-free way to monitor blood glucose, making regular checks easier for people with diabetes.
What could go wrong
This is a small, early-stage study with only 40 participants. The device is not yet FDA-approved and may not be as accurate as traditional methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jul 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population are patients from Taipei Medical University Shuang Ho Hospital and nearby volunteers.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals willing to sign an informed consent form. 2. Adults aged 18 to 80 years. 3. Individuals with a past medical history diagnosed by a physician as meeting the following criteria, totaling 45 participants: A. Healthy participants (15 individuals): fasting blood glucose \<100 mg/dL, HbA1c \<5.7%. B. Pre-diabetic participants (15 individuals): fasting blood glucose ≤100 mg/dL and \<126 mg/dL, HbA1c ≤5.7% and \<6.5%. C. Patients with type 2 diabetes (15 individuals): fasting blood glucose ≥126 mg/dL, HbA1c ≥6.5%, and no insulin injection. 4. The proportion of males and females in each group is \>30%. 5. Meets the signal acceptance criteria of the Cmate blood glucose analyzer. Exclusion Criteria: 1. Individuals who refuse to sign the informed consent form. 2. Adults who lack legal capacity. 3. Individuals under the age of 18 or over the age of 80. 4. Individuals with a history of major cardiac conditions such as stroke, myocardial infarction, heart failure, coronary artery bypass surgery, stent placement, or pacemaker implantation. 5. Individuals with controlled heart disease who, during the screening visit, were found to have signal characteristics that cannot be used when screened with the Cmate blood glucose analyzer. 6. Type 1 diabetes patients. 7. Individuals with a history of gestational diabetes. 8. Pregnant women. 9. Individuals with fasting blood glucose levels below 70 mg/dL or above 200 mg/dL within the past three months. 10. Individuals whose signal characteristics do not meet the acceptance criteria of the Cmate blood glucose analyzer. 11. Individuals deemed ineligible for inclusion by the study principal investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Glucose

Contacts and locations

Locations

  • Taipei Medical University Shuang Ho Hospital

    New Taipei City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.